Adoptive transfer of Tc17 CD8 T cells leads to tumor inhibition and anti-tumor response

AUTHORS:
Hung-Rong Yen1,2, Timothy J Harris1, Vedran Radojcic1, Dih-Dih Huang1, Joseph F Grosso1, Derese Getnet1, Satoshi Wada1, Monica V Goldberg1, Tullia C Bruno1, Nicholas Durham1, Khashayarsha Khazaie2, Leo Luznik1, Tzou-Yien Lin1, Drew M Pardoll1, Ching-Tai Huang3, Charles G Drake1

INSTITUTIONS:
1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
2. Graduate Institute of Clinical Medical Sciences, Chang Gung University, and Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
3. Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
4. Department of Pediatrics, Chang Gung Children's Hospital, Taoyuan, Taiwan.
5. Division of Gastroenterology and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

ABSTRACT: Although CD4+ T cells that secrete IL-17 (TH17) have been fairly well-studied, we and others have shown that CD8 T cells can be cultured under similar skewing conditions, resulting in CD8 cells with a robust ability to secrete IL-17. The physiological role such CD8 T cells (Tc17) is not well understood. In our previous data, we showed that Tc17 can functionally convert to IFN-γ producing cells, expand, and mediate autoimmunity in a self-antigen murine model. Because autoimmunity and antitumor immunity both involve the breaking of peripheral T cell tolerance, we performed experiments to test whether Tc17 could mediate anti-tumor immunity in implanted tumor models. In a preventive model, small numbers (0.1M) of sorted IFN-γ-producing Tc1, IL-17-producing or IFN-γ-producing Tc17 TCR-transgenic HA-recognizing CD8 T cells were adoptively transferred to immunocompetent recipient (Balb/C) mice on day -1, and 0.5M CT-26 tumor cells expressing HA as antigen were implanted into the footpad on day 0. Adoptive transfer of Tc17 was significantly superior to Tc1 in mediating an antitumor response and a better survival rate. Additional mechanisms are being explored.

Disclosure Information
Disclosure Information (Late-Breaking Non-Member): No Relationships
Funding Support (Late-Breaking Non-Member): Yes

Extra Info: CGD is a Damon Runyon-Lilly Clinical Investigator. This work was also supported by National Institutes of Health R01 CA127153 (CGD), K08 CA096948 (CGD), and the Patrick C. Walsh Fund. DMP is a Jamuey Scholar, holds the Seraph Chair for Cancer Research, and is supported in part by gifts from William and Betty Toperer, Dorothy Needle, and the Commonwealth Foundation. HRY is the recipient of a Taiwan Merit Scholarship from the National Science Council and Ministry of Education, as well as Chang Gung Medical Research Grants (CMRPG 350821 and 350822) from Chang Gung Memorial Hospital, Taiwan.